These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33295821)

  • 1. Recurrent neurosurgical site infection by extensively drug-resistant
    Bavaro DF; Romanelli F; Stolfa S; Belati A; Diella L; Ronga L; Fico C; Monno L; Mosca A; Saracino A
    Infect Dis (Lond); 2021 Mar; 53(3):206-211. PubMed ID: 33295821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
    Stevens RW; Clancy M
    Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 8. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
    Weaver K; Stallworth K; Blakely KK
    Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
    Silva JT; López-Medrano F
    Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis.
    Cipko K; Kizny Gordon A; Adhikari S; Konecny P
    Int J Infect Dis; 2021 Aug; 109():108-111. PubMed ID: 34157388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.
    Pybus CA; Felder-Scott C; Obuekwe V; Greenberg DE
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
    J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
    Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ
    Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of cefiderocol resistance in
    Teran N; Egge SL; Phe K; Baptista RP; Tam VH; Miller WR
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0100923. PubMed ID: 38063509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
    Drwiega EN; Griffith NC; Danziger LH
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.